Company description

Cocrystal Pharma, Inc. (ticker symbol COCP) is a biotechnology company that specializes in the development of novel antiviral therapeutics for the treatment of serious viral diseases. Founded in 2007, the company is headquartered in Bothell, Washington, with additional research and development facilities in Tucker, Georgia and Piscataway, New Jersey. COCP utilizes its proprietary structure-based drug discovery technology to design and develop small molecule antiviral drugs that target various viral infections, such as Hepatitis C, influenza, and Norovirus. The company's lead product candidate is an oral therapy for treatment of hepatitis C virus (HCV) infections, which is currently in phase IIa clinical trials. Additionally, COCP has collaborations with various pharmaceutical companies and research organizations to accelerate the development of its pipeline products. The company has a team of experienced scientists and executives who are dedicated to advancing its mission of providing effective and affordable treatment options for patients with viral infections. With a strong focus on innovation and cutting-edge research, COCP is poised for significant growth and success in the field of antiviral therapeutics.